title: Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.
abstract: We conducted this study to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a first-line treatment for patients with advanced gastric cancer. In all, 52 patients received courses of docetaxel 60 mg m(-2) intravenously (i.v.) for 1 h and then cisplatin 75 mg m(-2) i.v. for 2 h on day 1. Oral UFT at 400-600 mg day(-1), as determined by body surface area, and leucovorin at 75 mg day(-1) were administered for 21 consecutive days from day 1, and this was followed by a 7-day drug-free interval. A total of 225 courses were administered, and the median number of courses per patient was four. Four complete responses (7.7%) and 22 partial responses (42.3%) were achieved, giving an overall response rate of 50% (95% Confidence Interval: 36.4-63.6%). The major toxicity was neutropenia, which reached grade 3/4 in 36 patients (69.3%). Grade 3/4 nausea and vomiting was observed in 12 patients (23.1%). Median time to progression was 22 weeks (4 to 156+ weeks), median survival duration was 48 weeks (4 to 156+ weeks), and median response duration was 24 weeks (6-152 weeks). We conclude that docetaxel, cisplatin, oral UFT, and leucovorin combination chemotherapy is effective and tolerable for the treatment of advanced gastric cancer.
authors.affiliation: Department of Internal Medicine, Division of Hematology/Oncology, Korea University Medical Center, Anam Hospital, 126-1, 5-Ga Anam-Dong, Sungbuk-Gu, Seoul 136-705, Korea.
authors.forename: S C
authors.initials: SC
authors.lastname: Oh
authors.forename: K H
authors.initials: KH
authors.lastname: Park
authors.forename: I K
authors.initials: IK
authors.lastname: Choi
authors.forename: S Y
authors.initials: SY
authors.lastname: Yoon
authors.forename: S J
authors.initials: SJ
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Seo
authors.forename: C W
authors.initials: CW
authors.lastname: Choi
authors.forename: B S
authors.initials: BS
authors.lastname: Kim
authors.forename: S W
authors.initials: SW
authors.lastname: Shin
authors.forename: J S
authors.initials: JS
authors.lastname: Kim
authors.forename: Y H
authors.initials: YH
authors.lastname: Kim
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C096910:UFT(R) drug; D005641:Tegafur; D000077143:Docetaxel; D014498:Uracil; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Oncology. 2002;63(3):239-47
references.pmid: 12381903
references.citation: Eur J Cancer. 1994;30A(9):1263-9
references.pmid: 7999410
references.citation: Ann Oncol. 2003;14 Suppl 2:ii41-4
references.pmid: 12810457
references.citation: Jpn J Clin Oncol. 2002 Jul;32(7):248-54
references.pmid: 12324575
references.citation: Cancer Res Treat. 2002 Apr;34(2):77-83
references.pmid: 26680846
references.citation: Cancer Treat Rev. 1988 Dec;15(4):257-77
references.pmid: 3071419
references.citation: Cancer. 1993 Jun 15;71(12):3813-8
references.pmid: 8508349
references.citation: J Clin Oncol. 1994 Jan;12(1):14-20
references.pmid: 7677801
references.citation: Cancer. 1999 Jan 15;85(2):295-301
references.pmid: 10023695
references.citation: Semin Oncol. 1990 Feb;17(1 Suppl 2):61-70
references.pmid: 2305269
references.citation: Ann Oncol. 2000 Mar;11(3):301-6
references.pmid: 10811496
references.citation: Gan To Kagaku Ryoho. 1998 Oct;25(12):1915-24
references.pmid: 9797814
references.citation: Cancer Treat Rev. 1993 Jan;19(1):29-44
references.pmid: 8431925
references.citation: Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):119-23
references.pmid: 9348583
references.citation: Br J Cancer. 1994 Aug;70(2):380-3
references.pmid: 7914428
references.citation: Med Oncol. 1996 Jun;13(2):87-93
references.pmid: 9013471
references.citation: Gan To Kagaku Ryoho. 1999 Mar;26(4):487-96
references.pmid: 10097745
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3605-16
references.pmid: 12202661
references.citation: CA Cancer J Clin. 1994 Jan-Feb;44(1):7-26
references.pmid: 8281473
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3617-27
references.pmid: 12202662